Different therapeutic responses to osimertinib as first-line treatment for cavitated and non-cavitated squamous cell lung cancer with rare EGFR exon 19 deletion: two case reports and a literature review. The gene discussed is EGFR; the disease is squamous cell lung carcinoma.